Lumos Diagnostics Holdings Ltd. · ASX:LDX

Lumos Diagnostics — FY2022 Earnings Presentation

16 slides from Lumos Diagnostics's earnings presentation, Aug 26, 2022

  1. Slide 1: Lumos Diagnostics Holdings Limited FY22 Investor Presentation

    Lumos Diagnostics Holdings Limited FY22 Investor Presentation 26th August 2022 © Lumos Diagnostics, all rights reserved www.lumosdiagnostics.com 1

  2. Slide 2: Disclaimer and Important Information

    Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “

  3. Slide 3: FY22 Summary

    FY22 Summary “ Having come from a long career US$11.6 million total revenue in FY22 38% decrease vs FY21 in the diagnostics industry, I joined Lumos with a deep US$9.4 million Commercial Services business unit revenue in FY22 45% decrease vs FY21 understanding of the needs of the industry and of the

  4. Slide 4: Company Overview

    Company Overview

  5. Slide 5: Lumos Value Streams

    Lumos Value Streams © Lumos Diagnostics, all rights reserved DIGITAL READER TECHNOLOGY PLATFORM POINT OF CARE DIAGNOSTIC PRODUCTS 5

  6. Slide 6: Commercial Services - FY22 Operational Summary

    Commercial Services - FY22 Operational Summary • Lumos commercial services revenue of US$9.4 million (v US$17.1 million FY21) - normalisation to pre-pandemic growth profile (US$5.3 million in FY20). • Provided development services on 11 active customer projects during FY22. • Transition of developme

  7. Slide 7: Lumos-branded Product Business - FY22 Summary

    Lumos-branded Product Business - FY22 Summary BACTERIAL VS VIRAL INFECTION 3-IN-1 COVID-19/FLU A/FLU B TEST SARS-COV-2 RAPID ANTIGEN TEST • Regulatory clearances for FebriDx in • Validation and verification work for • Interim Order (IO) authorization Brazil and UAE. the 3-ViraDx test completed. from

  8. Slide 8: Financial Highlights

    Financial Highlights

  9. Slide 9: Financial Summary – FY22

    Financial Summary – FY22 All numbers in USD • Total revenue $11.6m, down 38% from $18.8m in FY21 Revenue • Services revenue $9.4m, compared to $17.1m in FY21 • Product revenue $2.2m , compared to $1.7m in FY21 Gross • Total gross profit $4.5m, $8.6m in FY21 Profit • Overall gross profit margin at 38

  10. Slide 10: Income Statement

    Income Statement All numbers in USD FY2022 FY2021 • Revenue $11.6m, down 38% on FY21 $'000 $'000 Revenue 11,630 18,854 • Services revenue $9.4m - down from FY21 high of COVID driven projects Cost of sales (7,174) (10,253) (77% higher than FY20 revenue of $5.3m) Gross profit 4,456 8,601 • Product rev

  11. Slide 11: Restructure and Rationalization

    Restructure and Rationalization All numbers in USD • Commenced a right-sizing and rationalization program to reduce costs and monthly cash usage • Headcount reduced from around 135 to 54 • Consolidate operations in Carlsbad, CA and close the Sarasota, FL facility • A number of one-off, impairment ch

  12. Slide 12: Balance Sheet

    Balance Sheet All numbers in USD June 2022 June 2021 $'000 $'000 Current assets • Cash and cash equivalents at 30 June of US$8.0m Cash and cash equivalents 7,978 44,890 Trade and other receivables 1,890 4,255 • Receivables $1.9m, net of $2.2m provision for doubtful debts Inventories 2,526 4,439 Prep

  13. Slide 13: Cash Flow

    Cash Flow All numbers in USD FY2022 FY2021 $'000 $'000 Cash flows from operating activities Receipts from customers (inclusive of GST) 12,456 20,726 Payments to suppliers (inclusive of GST) (30,337) (31,562) • Opening cash $27.3m – excluding the proceeds from sell down shares Proceeds from governmen

  14. Slide 14: Outlook

    Outlook

  15. Slide 15: Promising Outlook

    Promising Outlook “ I believe we are entering the new financial year in a stronger Growth through focus on strategic services partnerships position, as a much more focused and streamlined company. Continue to minimise burn and improve cash position There is little doubt in my mind that POC diagnosti

  16. Slide 16: © Lumos Diagnostics, all rights reserved

    © Lumos Diagnostics, all rights reserved www.lumosdiagnostics.com 16

Lumos Diagnostics Holdings — FY2022 Earnings Presentation on 6ix